The Technetium-99m Market size was US$ 4.54 billion in 2024 and is expected to reach US$ 6.03 billion by 2031. The Technetium-99m market size is estimated to register a CAGR of 4.2% during 2025-2031.

The U.S. Technetium-99m market is expanding steadily, driven by advanced healthcare infrastructure, high patient awareness, and widespread adoption of nuclear medicine imaging. Hospitals and diagnostic centers are increasingly investing in hybrid imaging systems such as SPECT/CT to enhance diagnostic accuracy and workflow efficiency. The growing prevalence of cardiovascular diseases, cancer, and bone disorders is fueling demand for Tc-99m-based imaging across cardiology, oncology, and bone scans. Technological innovations, including cadmium-zinc-telluride (CZT) detectors and advanced reconstruction software, are further improving image quality, reducing scan times, and minimizing radiation exposure for patients. Strong Mo-99/Tc-99m generator supply chains ensure consistent availability of Tc-99m radiopharmaceuticals, supporting routine clinical use. In addition, ongoing research into novel tracers for tumor and neurological imaging is expected to expand clinical applications, reinforcing Tc-99m's dominance as the preferred diagnostic isotope in the U.S. healthcare market.

The Middle East and Africa (MEA) Technetium-99m (Tc-99m) market is emerging as a region of significant growth potential, driven by increasing investment in healthcare infrastructure, rising awareness of nuclear medicine, and growing prevalence of chronic diseases. Countries such as Saudi Arabia, UAE, South Africa, and Egypt are at the forefront, with governments actively supporting the adoption of advanced diagnostic technologies. Hospitals and diagnostic centers are expanding nuclear medicine capabilities to include hybrid imaging systems like SPECT/CT, improving diagnostic precision for cardiovascular, oncology, bone, and other organ-specific applications.

The rising burden of cardiovascular diseases, cancer, and respiratory disorders in the region is increasing demand for Tc-99m-based imaging procedures. Investments in healthcare infrastructure, particularly in private hospitals and specialized diagnostic centers, are supporting the installation of advanced imaging equipment. Additionally, collaborations with global suppliers and technology providers are helping regional facilities access the latest imaging innovations, including CZT detectors and advanced image reconstruction software.

Despite certain challenges such as high equipment costs and limited trained personnel, the MEA market is benefiting from growing government initiatives promoting healthcare modernization, including improved access to radiopharmaceuticals and enhanced regulatory support. The availability of reliable Mo-99/Tc-99m generators ensures consistent supply, enabling routine diagnostic use. With increasing patient awareness, healthcare investments, and adoption of modern imaging technologies, the MEA Technetium-99m market is expected to experience steady and sustained growth over the coming years.

Lantheus Holdings Inc; Curium; Jubilant Radiopharma; NorthStar Medical Radioisotopes, LLC; Sun RadioPharma (Sun Pharmaceutical Industries, Inc.); NTP Radioisotopes SOC Ltd; Cardinal Health Inc; Medi-Radiopharma; Eckert & Ziegler AG; and Isotope JSC are among the key Technetium-99m market players that are profiled in this market study.

The overall Technetium-99m market size has been derived using both primary and secondary sources. Exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the EMEA Technetium-99m market size. The process also helps obtain an overview and forecast of the market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and gain analytical insights. This process includes industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the EMEA Technetium-99m market.